Pharmacokinetics of 5-Fluorouracil in Colorectal Cancer
Author Information
Author(s): J.A. Goldberg, D.J. Kerr, D.G. Watson, N. Willmott, C.D. Bates, J.H. McKillop, C.S. McArdle
Primary Institution: University Department of Surgery, Glasgow Royal Infirmary
Hypothesis
Does the administration of 5-fluorouracil via hepatic artery reduce systemic drug exposure compared to intravenous infusion?
Conclusion
The study found that intra-arterial administration of 5-fluorouracil significantly reduces systemic exposure compared to intravenous infusion.
Supporting Evidence
- Plasma concentrations of 5-fluorouracil were lower with intra-arterial administration compared to intravenous.
- Clearance values were higher for intra-arterial administration.
- Co-administration with angiotensin II and microspheres did not significantly reduce systemic drug levels.
Takeaway
This study looked at how a cancer drug is given to patients with liver cancer. It found that giving the drug directly into the liver can help reduce side effects.
Methodology
Seven patients received 5-fluorouracil via intrahepatic arterial infusion and intravenous infusion, with pharmacokinetic parameters measured.
Limitations
The study had a small sample size and did not measure drug concentrations in the tumor.
Participant Demographics
Patients with advanced colorectal hepatic metastases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website